Back to journals
Academic JournalOpen Access

Journal of Psychedelic Studies

37 Papers Indexed in Blossom

Data updated

Publication Landscape

How the 37 psychedelic papers Blossom tracks from Journal of Psychedelic Studies line up by year, topic and compound. This is the journal's psychedelic-research output in Blossom's records as of July 2026; its full catalogue is much larger.

How much psychedelic research does Journal of Psychedelic Studies carry?

Sourced

Tracked papers by publication year. Click a year for the running total.

7papers published in 2021

+600% vs 2020

18 published by 2021

Browse papers→

Don't read as the journal's total output: only the 37 of 37 tracked psychedelic papers from Journal of Psychedelic Studies with a recorded publication date are counted, and Blossom tracks only psychedelic-relevant papers, so the full catalogue is much larger. The current year is still filling in.

What does Journal of Psychedelic Studies publish on?

Sourced

Tracked papers per topic. Orange marks the largest research focus.

Depressive Disorders
17
Addiction & Substance Use
16
Anxiety Disorders
15
PTSD
7
Personality & Trait Factors
6
Safety & Risk Management
5
Palliative & End-of-Life Distress
5
Set & Setting
5
Other
37

Don't read shares as adding to 100%: a paper tagged with several topics counts once per topic. These are the psychedelic-relevant papers Blossom tracks, not the journal's full catalogue.

Which compounds does Journal of Psychedelic Studies cover?

Sourced

Tracked papers per compound. Orange marks the most-covered compound.

Ibogaine
8
Psilocybin
7
Ayahuasca
5
LSD
3
MDMA
1
Ketamine
1
5-MeO-DMT
1

Don't read shares as adding to 100%: a paper studying several compounds counts once per compound, and placebo comparator arms are not shown. These are the psychedelic-relevant papers Blossom tracks.

Research Footprint

Journal of Psychedelic Studies has 37 tracked papers indexed in Blossom (2016–2026) from 120 authors, most often covering Ibogaine, Psilocybin and Ayahuasca, across Depressive Disorders, Substance Use Disorders (SUD) and Anxiety Disorders.

Published Papers

Open Accessindividual

Ibogaine for the treatment of Parkinson's disease: A case report

This case study (n=1) reports that an 80-day course of low-dose ibogaine hydrochloride in a woman with Parkinson's disease was followed by improvements in motor symptoms, quality of life, fatigue and depression, but worse sleep. No adverse events were recorded.

Published
Journal
Journal of Psychedelic Studies
Authors
Erny, T., Cano Montenegro, E. Y., Barth, J., Noller, G.
Open Accessindividual

Assessing readiness for implementation of psychedelic-assisted mental health therapy, in low- and middle-income countries

This observational study assessed how ready 136 low- and middle-income countries are to implement psychedelic-assisted mental health therapy using 34 criteria covering disease burden, mental health services, payment, legal rules and cultural familiarity. South Africa, Thailand, Mexico, Brazil and Jamaica ranked highest overall, while 25 countries did not score highly in any domain.

Published
Journal
Journal of Psychedelic Studies
Authors
Lam, K., Griffin, C., Kantipudi, S., Mwai, D., Kahn, J. G., Marseille, E.
Open Accessindividual

Experiences of psychedelic drug use among people with psychotic symptoms and disorders: Personal growth and mystical experiences

In a retrospective online survey of 100 people with psychotic symptoms or disorders, most reported that a memorable psychedelic experience produced personal growth, mystical-type experiences, increased spirituality and insight, and some symptomatic improvement. However, 11% reported overall negative experiences (including symptom exacerbation, dysphoria and terror) and a slightly larger portion reported mixed outcomes.

Published
Journal
Journal of Psychedelic Studies
Authors
Torre, J. T. L., Gallo, J., Mahammadli, M., Zalewa, D., Williams, M. T.
Open Accessindividual

Attitudes of psychedelic users regarding cost of treatment and non-hallucinogenic alternatives

In a survey of 1,221 naturalistic psychedelic users, 76% judged altered states of consciousness to be very or extremely important for therapeutic effects, yet 61% said they would be willing to try a non-hallucinogenic analogue. Respondents considered about $70–80 per hour a reasonable fee for preparation, dosing and integration—substantially below current market projections for psychedelic-assisted psychotherapy.

Published
Journal
Journal of Psychedelic Studies
Authors
Aday, J. S., Boehnke, K. F., Herberholz, M., Kruger, D. J.
Open Accessindividual

Perceived attachment history predicts psychedelic experiences: A naturalistic study

In an international Jewish sample (N = 185) who reported memorable psychedelic use, perceived insecure early attachment was positively associated with stronger psychedelic phenomenology (mystical, challenging, emotional breakthrough, ego dissolution, sensed presence), whereas current adult attachment orientations were unrelated and psychedelic experiences generally did not attenuate the link between perceived insecure attachment history and present attachment insecurity.

Published
Journal
Journal of Psychedelic Studies
Authors
Cherniak, A. D., Mikulincer, M., Brulin, J. G., Granqvist, P.
Open Accessindividual

Perceptions of psychedelic personality change, determinants of use, setting and drug moderation: Toward a holistic model

Analysing free-text reports from psychedelic users and survey data from users and non‑users, the study identified 52 distinct perceived personality‑change themes that aggregated into eight higher‑order factors and showed that openness, extraversion and neuroticism predict interest in and outcomes of psychedelic use. These results support a tentative holistic model in which baseline personality, drug type and setting interact to produce diverse, clinically relevant personality changes, and they point to directions for prospective research and psychedelic‑assisted therapies.

Published
Journal
Journal of Psychedelic Studies
Authors
Weiss, B., Sleep, C., Beller, N., Erritzoe, D., Campbell, W. K.

Quick Facts

Papers Indexed
37
h-Index
14
Open Access
Yes
Publisher
Akadémiai Kiadó
Country
Hungary
Website
Visit